Haura, Eric B.

Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs

Kris, M. G., Johnson, B. E., Berry, L. D., Kwiatkowski, D. J., Iafrate, A. J., Wistuba, I. I., Varella-Garcia, M., Franklin, W. A., Aronson, S. L., Su, P.-F., et al. (2014) · JAMA

Lung Cancer Treatments and MutationsCancer Genomics and Diagnostics

Cited by 1,724

Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis

Niu, G., Wright, K. L., Huang, M., Song, L., Haura, E., Turkson, J., Zhang, S., Wang, T., Sinibaldi, D., Coppola, D., et al. (2002) · Oncogene

Angiogenesis and VEGF in CancerCytokine Signaling Pathways and Interactions

Cited by 1,207

Src kinases as therapeutic targets for cancer

Kim, L. C., Song, L., & Haura, E. B. (2009) · Nature Reviews Clinical Oncology

Cancer Mechanisms and TherapyProtein Kinase Regulation and GTPase Signaling

Cited by 700

A Phase II Study of PD-0325901, an Oral MEK Inhibitor, in Previously Treated Patients with Advanced Non–Small Cell Lung Cancer

Haura, E. B., Ricart, A. D., Larson, T. G., Stella, P. J., Bazhenova, L., Miller, V. A., Cohen, R. B., Eisenberg, P. D., Selaru, P., Wilner, K. D., et al. (2010) · Clinical Cancer Research

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 237

The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations—The Lung Cancer Mutation Consortium (LCMC2)

Aisner, D. L., Sholl, L. M., Berry, L. D., Rossi, M. R., Chen, H., Fujimoto, J., Moreira, A. L., Ramalingam, S. S., Villaruz, L. C., Otterson, G. A., et al. (2018) · Clinical Cancer Research

Lung Cancer Treatments and MutationsCancer Genomics and Diagnostics

Cited by 206

Neoadjuvant atezolizumab in resectable non-small cell lung cancer (NSCLC): Interim analysis and biomarker data from a multicenter study (LCMC3).

Kwiatkowski, D. J., Rusch, V. W., Chaft, J. E., Johnson, B. E., Nicholas, A., Wistuba, I. I., Merritt, R., Lee, J. M., Bunn, P. A., Tang, Y., et al. (2019) · Journal of Clinical Oncology

Cancer Immunotherapy and BiomarkersLung Cancer Diagnosis and Treatment

Cited by 146

Cell Type–Specific Adaptive Signaling Responses to KRASG12C Inhibition

Solanki, H. S., Welsh, E. A., Fang, B., Izumi, V., Darville, L., Stone, B., Franzese, R., Chavan, S., Kinose, F., Imbody, D., et al. (2021) · Clinical Cancer Research

Protein Kinase Regulation and GTPase SignalingLung Cancer Treatments and Mutations

Cited by 106

Collateral sensitivity networks reveal evolutionary instability and novel treatment strategies in ALK mutated non-small cell lung cancer

Dhawan, A., Nichol, D., Kinose, F., Abazeed, M. E., Marusyk, A., Haura, E. B., & Scott, J. G. (2017) · Scientific Reports

Lung Cancer Treatments and MutationsCancer Genomics and Diagnostics

Cited by 79

A12 The SHP2 Inhibitor RMC-4630 in Patients with KRAS-Mutant Non-Small Cell Lung Cancer: Preliminary Evaluation of a First-in-Man Phase 1 Clinical Trial

Ou, S. I., Koczywas, M., Ulahannan, S., Janne, P., Pacheco, J., Burris, H., McCoach, C., Wang, J. S., Gordon, M., Haura, E., et al. (2020) · Journal of Thoracic Oncology

Protein Tyrosine PhosphatasesLung Cancer Treatments and Mutations

Cited by 73

Randomized-controlled phase II trial of salvage chemotherapy after immunization with a TP53-transfected dendritic cell-based vaccine (Ad.p53-DC) in patients with recurrent small cell lung cancer

Chiappori, A. A., Williams, C. C., Gray, J. E., Tanvetyanon, T., Haura, E. B., Creelan, B. C., Thapa, R., Chen, D.-T., Simon, G. R., Bepler, G., et al. (2019) · Cancer Immunology, Immunotherapy

Immunotherapy and Immune ResponsesLung Cancer Research Studies

Cited by 64

Phase I Study of JNJ-74699157 in Patients with Advanced Solid Tumors Harboring the KRAS G12C Mutation

Wang, J., Martin-Romano, P., Cassier, P., Johnson, M., Haura, E., Lenox, L., Guo, Y., Bandyopadhyay, N., Russell, M., Shearin, E., et al. (2022) · The Oncologist

Protein Kinase Regulation and GTPase SignalingLung Cancer Treatments and Mutations

Cited by 60

MEK inhibitors block growth of lung tumours with mutations in ataxia–telangiectasia mutated

Smida, M., Fece de la Cruz, F., Kerzendorfer, C., Uras, I. Z., Mair, B., Mazouzi, A., Suchankova, T., Konopka, T., Katz, A. M., Paz, K., et al. (2016) · Nature Communications

Lung Cancer Treatments and MutationsMelanoma and MAPK Pathways

Cited by 44

A phase I study of tasisulam sodium (LY573636 sodium), a novel anticancer compound in patients with refractory solid tumors

Simon, G. R., Ilaria, R. L., Sovak, M. A., Williams, C. C., Haura, E. B., Cleverly, A. L., Sykes, A. K., Wagner, M. M., de Alwis, D. P., Slapak, C. A., et al. (2011) · Cancer Chemotherapy and Pharmacology

Cancer therapeutics and mechanismsStatistical Methods in Clinical Trials

Cited by 19

Non-canonical IKKs, IKKϵ and TBK1, as novel therapeutic targets in the treatment of non-small cell lung cancer

Kim, J.-Y., Beg, A. A., & Haura, E. B. (2013) · Expert Opinion on Therapeutic Targets

NF-κB Signaling PathwaysLung Cancer Treatments and Mutations

Cited by 17

Phase II randomized trial of first-line pembrolizumab and vorinostat in patients with metastatic NSCLC (mNSCLC): Final results.

Saltos, A. N., Tanvetyanon, T., Creelan, B. C., Shafique, M. R., Antonia, S. J., Haura, E. B., Zheng, H., Yu, X., Saller, J. J., Viracacha, S., et al. (2023) · Journal of Clinical Oncology

Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations

Cited by 9